Page last updated: 2024-12-11

ramiprilat

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ramiprilat : A dipeptide that is the active metabolite of ramipril. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5464096
CHEMBL ID1201365
CHEBI ID77363
SCHEMBL ID467411
MeSH IDM0149113

Synonyms (33)

Synonym
ramiprilatum [latin]
ramiprilat
ramiprilat [inn]
(2s,3as,6as)-1-((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
ramiprilate [french]
chebi:77363 ,
ramipril diacid
CHEMBL1201365
87269-97-4
ramiprilate
6n5u4qfc3g ,
unii-6n5u4qfc3g
ramiprilatum
ramipril impurity e [ep impurity]
AKOS015913740
gtpl6344
(2s,3as,6as)-1-[(2s)-2-[[(2s)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[d]pyrrole-2-carboxylic acid
SCHEMBL467411
(2s,3as,6as)-1-[(2s)-2-{[(1s)-1-carboxy-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid
(2s,3as,6as)-1-[(2s)-2-[[(1s)-1-carboxy-3-phenylpropyl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (ramipril diacid; ramiprilat)
ramiprilat (ramipril diacid)
(2s,3as,6as)-1-(((s)-1-carboxy-3-phenylpropyl)-l-alanyl)octahydrocyclopenta[b]pyrrole-2-carboxylic acid
DB14208
Q27088514
DTXSID401016165 ,
(2s,3as,6as)-1-[(2s)-2-[[(1s)-1-carboxy-3-phenylpropyl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrole-2-carboxylic acid
AS-6150
D82060
HY-A0115
ramiprilatum (latin)
(2s,3as,6as)-1-((2s)-2-(((1s)-1-carboxy-3-phenylpropyl)amino)propanoyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
dtxcid801474301
ramipril impurity e (ep impurity)

Research Excerpts

Overview

Ramiprilat is an angiotensin I-converting enzyme (ACE) inhibitor. lipophilicity may modify its inhibitory activity.

ExcerptReferenceRelevance
"Ramiprilat is an angiotensin I-converting enzyme (ACE) inhibitor whose particular lipophilicity may modify its inhibitory activity on the cellular form of this enzyme in comparison to ACE inhibitors that are more hydrophilic. "( In vitro interactions between ramiprilat and angiotensin I-converting enzyme in endothelial cells.
Baudin, B; Drouet, L, 1989
)
2.01

Treatment

Pretreatment with ramiprilat 100 nmol/L for 15 minutes significantly attenuated the recovery of B2 kinin receptors in CR membranes. The effects were reversed by the B(2) receptor antagonist icatibant (Hoe 140) and by the NO synthase inhibitor N(G)-nitro-L-arginine.

ExcerptReferenceRelevance
"Treatment with ramiprilat could abolish this isoform-specific PKC regulation in both areas."( Mechanisms of myocardial remodeling: ramiprilat blocks the expressional upregulation of protein kinase C-epsilon in the surviving myocardium early after infarction.
Braun, MU; Kirrstetter, M; Schön, SP; Simonis, G; Strasser, RH, 2003
)
0.93
"Pretreatment with ramiprilat 100 nmol/L for 15 minutes significantly attenuated the recovery of B2 kinin receptors in CR membranes while increasing that from membranes lacking caveolin."( Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells.
Benzing, T; Blaukat, A; Busse, R; Fleming, I; Müller-Esterl, W, 1999
)
0.89
"Pretreatment with ramiprilat, an angiotensin-converting enzyme (ACE) inhibitor, induced cardioprotection and its possible mechanism of action was investigated in guinea-pig Langendorff perfused heart."( Pretreatment with ramiprilat induces cardioprotection against free radical injury in guinea-pig isolated heart: involvement of bradykinin, protein kinase C and prostaglandins.
Chen, X; Jin, ZQ, 2000
)
0.96
"Pretreatment with ramiprilat (0.3 micromol/L) or irbesartan (0.01 to 1 micromol/L) had no effect on basal ppET-1 or ET(B)-R expression but markedly attenuated the deformation-induced expression of these gene products, and these effects were reversed by the B(2) receptor antagonist icatibant (Hoe 140) and by the NO synthase inhibitor N(G)-nitro-L-arginine."( ACE inhibitor and AT1 antagonist blockade of deformation-induced gene expression in the rabbit jugular vein through B2 receptor activation.
Cattaruzza, M; Hecker, M; Lauth, M, 2001
)
0.63

Toxicity

ExcerptReferenceRelevance
"5 mg, administered after hemodialysis, appears to be safe and effective in hypertensive patients receiving periodic hemodialysis."( Kinetics, safety, and efficacy of ramipril after long-term administration in hemodialyzed patients.
Baguet, JC; Carcone, N; de la Rey, N; Dubois, D; Fillastre, JP; Genthon, R; Godin, M; Legallicier, B; Luus, HG; Vauquier, J, 1996
)
0.29

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic data were collected at baseline, 4 weeks, and 1 year."( The pharmacokinetics of ramipril in a group of ten elderly patients with essential hypertension.
Hosie, J; Meredith, P, 1991
)
0.28
"1 ng/ml after the first dose, and a peak concentration of 26."( Multiple-dose pharmacokinetics of ramipril in patients with chronic congestive heart failure.
Bender, N; Brockmeier, D; Heintz, B; Lückel, G; Maigatter, S; Rangoonwala, B; Sieberth, HG; Verho, M, 1993
)
0.29
" The present paper discusses how tight binding of ramiprilat to ACE affects the pharmacokinetic characteristics and in vitro measurement of ACE inhibition."( Tight binding of ramiprilat to ACE: consequences for pharmacokinetic and pharmacodynamic measurements.
Brockmeier, D, 1995
)
0.88
" The linear ranges correspond well with the serum concentrations of the analytes obtained in clinical pharmacokinetic studies."( High-performance liquid chromatography-mass spectrometric analysis of ramipril and its active metabolite ramiprilat in human serum: application to a pharmacokinetic study in the Chinese volunteers.
Liu, J; Lu, XY; Shen-Tu, JZ, 2006
)
0.55
" This paper describes the first human physiologically based pharmacokinetic (PBPK) model of this drug class."( Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat.
Levitt, DG; Schoemaker, RC, 2006
)
0.56
"We conducted 3 open-label, multiple-dose, 3-period, randomized, crossover studies in healthy subjects to assess the potential pharmacokinetic interaction between vildagliptin, a novel dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes, and representatives of 3 commonly prescribed antihypertensive drug classes: (1) the calcium channel blocker, amlodipine; (2) the angiotensin receptor blocker, valsartan; and (3) the angiotensin-converting enzyme inhibitor, ramipril."( Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
Campestrini, J; Dole, K; Dole, WP; He, YL; Howard, D; Ligueros-Saylan, M; Marion, A; Pommier, F; Sabo, R; Sunkara, G; Wang, Y; Zhao, C, 2008
)
0.35
" The pharmacodynamic effects were assessed by measuring plasma angiotensin-converting enzyme (ACE) activity."( Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat in healthy cats.
Burgaud, S; Desmoulins, PO; Horspool, LJ, 2008
)
0.59

Bioavailability

ExcerptReferenceRelevance
" Systemic bioavailability of ramiprilat after PO ramipril was 6-9%."( Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat after intravenous and oral doses of ramipril in healthy horses.
Castejón-Riber, C; Esgueva, M; Gómez-Díez, M; Mena-Bravo, A; Muñoz, A; Priego-Capote, F; Serrano Caballero, JM; Serrano-Rodríguez, JM, 2016
)
0.97

Dosage Studied

ExcerptRelevanceReference
" Furthermore, bradykinin did not modify the dose-response curves for added norepinephrine."( Importance of sympathetic innervation in the positive inotropic effects of bradykinin and ramiprilat.
Djokovic, A; Erdös, EG; Miletich, DJ; Minshall, RD; Rabito, SF; Vogel, SM; Yelamanchi, VP, 1994
)
0.51
" Measurable concentrations of ramipril were recorded in plasma after oral dosing (bioavailability approximately 45%), whereas in CSF the prodrug concentration was below the minimal determinable levels in most cases."( Central nervous and systemic kinetics of ramipril and ramiprilat in the conscious dog.
Abrahamsson, T; Ervik, M; Forshult, E; Nordström, M; Regårdh, CG, 1993
)
0.53
" Data from a randomized crossover study in healthy volunteers given 2 different dosage forms with 5 mg ramipril serve to compare the theoretically deduced predictions with actual measurements."( Tight binding of ramiprilat to ACE: consequences for pharmacokinetic and pharmacodynamic measurements.
Brockmeier, D, 1995
)
0.63
" Ramiprilat or mercaptoethanol induced leftward shifts in the BK dose-response curve (EC(50)=3."( Potentiation of the vascular response to kinins by inhibition of myocardial kininases.
Dendorfer, A; Dominiak, P; Inamura, N; Schäfer, U; Stewart, JM; Wolfrum, S, 2000
)
1.22
" No adjustment of the recommended PO dosage of ramipril is needed in dogs with moderate renal impairment."( Pharmacokinetic and pharmacodynamic parameters of ramipril and ramiprilat in healthy dogs and dogs with reduced glomerular filtration rate.
Jeunesse, E; Laroute, V; Lefebvre, HP; Toutain, PL,
)
0.37
" No adjustment in dosage based on pharmacokinetic considerations is required should vildagliptin be coadministered with amlodipine, valsartan, or ramipril in patients with type 2 diabetes and hypertension."( Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
Campestrini, J; Dole, K; Dole, WP; He, YL; Howard, D; Ligueros-Saylan, M; Marion, A; Pommier, F; Sabo, R; Sunkara, G; Wang, Y; Zhao, C, 2008
)
0.35
" The appropriateness of this dosage regime needs to be confirmed in diseased cats."( Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat in healthy cats.
Burgaud, S; Desmoulins, PO; Horspool, LJ, 2008
)
0.59
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitorAn EC 3.4.15.* (peptidyl-dipeptidase) inhibitor that interferes with the action of peptidyl-dipeptidase A (EC 3.4.15.1).
drug metabolitenull
cardioprotective agentAny protective agent that is able to prevent damage to the heart.
matrix metalloproteinase inhibitornull
bradykinin receptor B2 agonistA bradykinin agonist that binds to and activates bradykinin B2 receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
cyclopentapyrrole
azabicycloalkane
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
dicarboxylic acidAny carboxylic acid containing two carboxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Ramipril Action Pathway34
Ramipril Metabolism Pathway12

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1345457Human Angiotensin-converting enzyme (M2: Angiotensin-converting (ACE and ACE2))1984Arzneimittel-Forschung, , Volume: 34, Issue:10B
2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S) -2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498)--a new and highly effective angiotensin I converting enzyme inhibitor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (167)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (9.58)18.7374
1990's101 (60.48)18.2507
2000's37 (22.16)29.6817
2010's13 (7.78)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.49 (24.57)
Research Supply Index5.21 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (5.20%)5.53%
Reviews5 (2.89%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other159 (91.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]